Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hisamitsu Pharmaceutical Co ( (JP:4530) ) has issued an update.
Hisamitsu Pharmaceutical has announced a slate of 10 director candidates for election at its May 28, 2026 annual general meeting of shareholders, as the terms of all current directors expire. The proposal largely maintains continuity in governance, re-nominating President and CEO Kazuhide Nakatomi as representative director, retaining nine existing directors including three outside directors, and adding senior executive officer Sakae Yano as a new director while one outside director, Yuichiro Anzai, will step down, signaling a modest board refresh rather than a strategic overhaul.
The most recent analyst rating on (JP:4530) stock is a Hold with a Yen4300.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based pharmaceutical company known for developing and marketing prescription and over-the-counter medicines, including topical analgesic and other healthcare products. The company operates globally, with a focus on pain relief solutions and related therapeutic areas, and is led by President and CEO Kazuhide Nakatomi.
YTD Price Performance: 37.64%
Average Trading Volume: 497,326
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen441.1B
Find detailed analytics on 4530 stock on TipRanks’ Stock Analysis page.